What is on the Horizon for Rheumatology in 2023?

Nehad Soloman, MD, discusses the impact of new biosimilars to become available in the U.S. in 2023 on rheumatic disease management.

Dr Nehad Soloman provides insight on recent approvals and upcoming FDA submissions in biosimilars, including for lupus nephritis, and how they may change the course of rheumatic disease management moving forward.

An expert in rheumatology shares updates in clinical research that may shape rheumatic disease care in the future.

Nehad Soloman, MD, comments on the use of precision medicine and its advantages in the field of rheumatology.

Dr Nehad Solman reviews the role of clinical pathways and alternative payment models in rheumatology as well as anticipated changes for 2023.

An expert in rheumatology highlights challenges faced in the rheumatology workforce and how to optimize addressing these issues going forward.

Nehad Soloman, MD, provides final thoughts on what rheumatologists can look forward to in 2023 for rheumatic disease management.